Found: 3
Select item for more details and to access through your institution.
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Phase I dose-escalation oncology trials with sequential multiple schedules.
- Published in:
- 2021
- By:
- Publication type:
- journal article